



DFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: WARRINGTON=1

In re Application of:)	Confirmation No.: 3198
)	
WARRINGTON et al.)	Art Unit: 1623
)	
Appln. No.: 10/705,262)	Examiner:
)	
Filed: November 12, 2003)	Washington, D.C.
)	
For: METHOD OF TREATING AN)	May 17, 2004
INDIVIDUAL WITH METHYL...)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed before the mailing date of a first Office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., Form PTO/SB/08A) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an

attachment hereto. A copy of each document listed is attached, except as explained below.

[XX] Document AA is a U.S. patent and/or published application(s). As this is a U.S. application filed after June 30, 2003, or an entry into national stage under 35 USC §371 after June 30, 2003, the requirement to file copies of such U.S. patents or published applications has been waived. (Office of Patent Legal Administration - Pre O.G. Notice of July 11, 2003).


3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.


Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:


Sheridan Neimark
Reg. No. 20,520

SN:ft
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
G:\BN\C\ohn\WARRINGTON1\pto\14May04IDS.doc



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 2

Complete if Known

Application Number	10/705,262
Filing Date	November 12, 2003
First Named Inventor	WARRINGTON et al.
Group Art Unit	1623
Examiner Name	
Attorney Docket Number	WARRINGTON=1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AB	BAR-YEHUDA et al., "Agonists To The A3 Adenosine Receptor Induce G-CSF Production Via NF-κB Activation: A New Class Of Myeloprotective Agents", Experimental Hematology 30: (2002), 1390-1398	
	AC	BAR-YEHUDA et al., "Resistance of Muscle to Tumor Metastases: A Role for A3 Adenosine Receptor Agonists", Neoplasia (2001), Vol. 3, No. 2, 125-131.	
	AD	FISHMAN et al., "Adenosine Acts As An Inhibitor Of Lymphoma Cell Growth: A Major Role For The A3 Adenosine Receptor", European Journal Of Cancer, 36: (2000), 1452-1458.	
	AE	FISHMAN et al., "Adenosine Acts As A Chemoprotective Agent By Stimulating G-CSF Production: A Role For A1 and A3 Adenosine Receptors", Journal Of Cellular Physiology, 183: (2000), 393-398.	
	AF	FISHMAN et al., "Targeting The A3 Adenosine Receptor For Cancer Therapy: Inhibition Of Prostate Carcinoma Cell Growth By A3AR Agonist", Anticancer Research, 23: (2003) 2077-2083.	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.